Research programme: autologous cell therapy - NewNeural
Alternative Names: ACT-MD; ACT-N; Autologous cell therapy-NeurologicalLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator NewNeural
- Class Stem cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in USA (Injection)
- 28 Jul 2003 Preclinical trials in Stroke in USA (Injection)